secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2026-10-14T20:05:13+00:00
Accession:  0001683168-26-007845
Event type: other_material
Sentiment:  negative
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4.1-flash:cloud@v2

Sunshine Biopharma CEO's 90% consent approves discounted share issuance and Series D warrant repricing
--------------------------------------------------------------------------------

- Dr. Steve N. Slilaty, CEO and holder of ~90% of voting power, approved the matters by written consent on October 13, 2026.
- Consent covers issuing more than 20% of outstanding common stock at a deemed discount to the Nasdaq Minimum Price, tied to the public offering that closed October 9, 2026.
- Also approves exercise-price/share-count adjustments to Series D Warrants in a Share Combination Event (Section 3.7) and voluntary repricing of all outstanding Series D Warrants (Section 3.8).
- Consent becomes effective 20 days after the definitive information statement is mailed to stockholders.
- Common stock trades as SBFM and the purchase warrants as SBFMW on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826007845/0001683168-26-007845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826007845/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-007845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer